<DOC>
	<DOCNO>NCT00937846</DOCNO>
	<brief_summary>GSK1034702 develop improve cognitive impairment diseases Alzheimer 's disease schizophrenia . This study do healthy men investigate much study drug get brain . This do use Positron Emission Tomography ( PET ) .</brief_summary>
	<brief_title>Brain Uptake GSK1034702 : Positron Emission Tomography ( PET ) Scan Study</brief_title>
	<detailed_description>This open label , single dose , non-randomized PET study healthy male subject ascertain GSK1034702 cross blood-brain barrier enable elicit central effect . GSK1034702 show vitro substrate human Pgp , therefore distribution GSK1034702 human brain could adversely affect . This use PET conjunction radioactively label GSK1034702 help ascertain role Pgp play limit brain penetration presence absence pharmacological relevant oral non label dose 5 mg . Subjects MRI scan aid definition brain anatomy , baseline PET scan post-dose PET scan . For subject study consist least three visit ; screen visit , scan day follow-up .</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Generally healthy . Male 35 55 year age . Willing use appropriate contraception method . Weight 50 kg . BMI within range 19 29 kg/m2 . Adequate blood supply hand . Abuse drug alcohol . Smoker history regular use tobacco nicotinecontaining product past 6 month . ECG abnormality ( personal family history ) . Psychiatric disorder . Asthma history asthma . Medical illness . Worked welder , metal worker machinist . Suffers claustrophobia would unable lie still PET MRI scanner 12 hour . Has cardiac pacemaker electrical device ferromagnetic metal foreign body . Neurological disorder</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cognitive impairment</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>PET</keyword>
</DOC>